HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

(2016) Andrea De Luca et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease

(2015) Ankita Gupta et al.   BMC BIOINFORMATICS

Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1

(2013) K. A. Sutherland et al.   JOURNAL OF GENERAL VIROLOGY

FUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection

(2013) B. Murrell et al.   MOLECULAR BIOLOGY AND EVOLUTION

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

(2012) C Orkin et al.   HIV MEDICINE

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor

(2012) T. J. Barber et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Human Immunodeficiency Virus gag and protease: partners in resistance

(2012) Axel Fun et al.   Retrovirology

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

(2011) Pedro Cahn et al.   AIDS

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays

(2010) Ravindra K Gupta et al.   AIDS

Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy

(2010) E. Poveda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology

(2010) W. Delport et al.   BIOINFORMATICS

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

(2009) Sandra De Meyer et al.   AIDS

Gag Determinants of Fitness and Drug Susceptibility in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

(2009) C. M. Parry et al.   JOURNAL OF VIROLOGY

FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix

(2009) M. N. Price et al.   MOLECULAR BIOLOGY AND EVOLUTION

A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences

(2009) L. C. J. Alcantara et al.   NUCLEIC ACIDS RESEARCH

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen

(2008) Constance Delaugerre et al.   AIDS

POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients

(2008) A Pozniak et al.   Journal of the International AIDS Society